Articles tagged with Drug Discovery
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.
Researchers develop cellular model to reproduce NF1-associated tumour progression, identifying new therapeutic opportunities. The combination of olaparib and selumetinib shows promise in reducing tumour growth.
A large-scale Phase 3 trial of CRISPR therapy has shown an 87% reduction in attacks for patients with hereditary angioedema. The treatment also improved quality-of-life scores and reduced the need for on-demand medication, paving the way for future genetic therapies.
Physicists at UC Berkeley introduce phase contrast to electron microscopy, enabling clearer images of small molecules and structures inside cells. The laser phase plate enhances cryoelectron microscopy, overcoming signal-to-noise limitations and paving the way for new drug discovery.
Scripps Research team creates stereoretentive radical-radical cross-coupling, a simpler way to build chiral drug candidates while maintaining 3D structure. The new reaction uses a nickel catalyst and produces practical yields with high enantiospecificity.
The Acceleration Consortium and Structural Genomics Consortium collaborate to develop new drugs using AI-driven lab capabilities. The partnership aims to speed up the discovery of bioactive molecules, advancing human health and disease understanding.
Researchers summarize recent developments in terahertz biophotonics, highlighting its potential for overcoming technical limitations in fields like skin cancer diagnosis, wound assessment, and drug discovery. The study provides a roadmap for future research to improve the field's practical applications.
Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.
Andrew Yang's research has reshaped scientific understanding of the blood-brain barrier and its role in brain health and disease. His latest study reveals new potential treatment targets for neurological diseases, normal aging, and sleep.
Researchers at King's College London have developed a new approach called 'Efflux Resistance Breaker' (ERB), designed to overcome one way bacteria escape antibiotic treatment. This allows antibiotics to remain inside bacterial cells at higher concentrations, restoring their ability to kill bacteria even with resistance mechanisms present.
Researchers are using 3D cardiac constructs to model cardiovascular diseases and test new drugs. These constructs can capture the complexity of human cardiac tissue, including its electrical activity, metabolism, and cellular communication. The field is advancing with biomaterials, AI-assisted screening, and improved standardization.
Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.
The coalition aims to accelerate validation and qualification of human-relevant methodologies, such as complex in vitro models and microphysiological systems, for drug discovery and development. By aligning developers around shared qualification standards, the coalition reduces duplicative validation efforts and helps regulators evalua...
The ISSCR Consortium supports the FDA's draft guidance on using new approach methodologies (NAMs) in drug development, emphasizing the need for a flexible and science-driven framework. The consortium recommends clarifying biological complexity alignment with context of use and expanding recognition of computational modeling and hybrid ...
Researchers from Harrington Discovery Institute provide a new understanding of cancer processes and identify promising targets for treatments. They uncover a class of therapeutic targets that may complement existing therapies.
Researchers developed genESOM, a generative AI that can expand dataset volume and simulate larger animal numbers while maintaining reliability. This allows for 30-50% reduction in animal experiments without compromising results.
A team of researchers has uncovered a promising new target for antimalarial drug design, identifying an enzyme called aminopeptidase P from the Plasmodium falciparum parasite. The new inhibitors have been shown to bind more strongly and selectively than existing compounds, demonstrating potential as a new class of drugs to combat malaria.
The UK-led OpenBind initiative has released its first publicly available dataset and predictive AI model, accelerating the discovery of new medicines using artificial intelligence. The release showcases high-quality, standardized experimental data and a trained predictive model, enabling researchers worldwide to drive the next generati...
A new study published in Science Advances identifies IRS4 as a promising drug target for multiple solid tumors, offering hope for safer cancer treatments. By using AI and natural mutations, researchers prioritized targets with high therapeutic indexes to minimize toxicity.
Researchers have identified a gene, eIF4G2, crucial for keeping adult intestinal stem cells stable and functional. The study reveals that the gene plays a vital role in regulating protein production and maintaining stem cell identity.
Researchers used a new AI-powered computational method to discover that most nucleosomes contain sections of DNA that are partially accessible to the cell. The study found that more than 85% of nucleosomes showed some degree of distortion, with 14 distinct structural states associated with different levels of gene activity.
Researchers at the University of East Anglia have discovered that light can be programmed using its natural geometry, allowing for the creation of structured light with unique properties. This breakthrough has far-reaching implications for fields such as medicine, data transmission, and quantum technologies.
The kinase field offers significant therapeutic opportunities, with many understudied kinases waiting to be explored. Recent advances in chemical probe development and resource availability have led to a shift towards more systematic exploration of previously neglected targets.
A UCLA-led international collaboration has unveiled a new technology that enables scientists to directly compare how different molecules compete for the same binding site on a protein, all in a single experiment. The results show promising interactions between two cancer drugs and reveal previously unknown interactions.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
Dr. Dennis Slamon, a renowned breast cancer researcher, has been elected to the Association of American Physicians (AAP) for his pioneering work in HER2 gene discovery and targeted therapies. His research led to significant improvements in survival rates and established the principle of targeted cancer treatment.
A computational protocol has been established by University of Kent researchers to accurately identify reactions that can result in successful drug candidates for Chagas disease. This approach reduces the need for trial-and-error, prioritizing promising compounds earlier and making the drug discovery process faster and more affordable.
Researchers at the University of Cape Town have identified a critical molecular switch that drives the formation of cancer-associated antigens. By understanding how enzymes relocate within a cell, they have uncovered key mechanisms for tumorigenesis.
Researchers at Gladstone Institutes identified hundreds of human genes influencing HIV infection and two potent antiviral proteins, PI16 and PPID. These proteins block HIV's entry into T cells or limit its ability to replicate within the cell.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers Dr Íris Luz Batalha and Dr Maria Shchepinova from the University of Bath have been awarded funding to test new ideas in tackling global health challenges. They will develop precision-targeted therapies for antimicrobial resistance and investigate why treatments for Type 2 diabetes don't work for everyone.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
The VCU Massey Comprehensive Cancer Center has completed the inaugural funding cycle of its collaborative drug discovery program with the Sanford Burnham Prebys Medical Discovery Institute. Two projects have received $50,000 each to advance innovative cancer drug discovery efforts.
Gladstone Institutes investigator Ryan Corces receives $750,000 to investigate unknown genetic variants contributing to Alzheimer's disease. He aims to identify new drivers and therapeutic targets using artificial intelligence and CRISPR tools.
Scientists have found that the APOE4 gene variant causes hyperactivity in two regions of the hippocampus, an important memory center of the brain, even before middle age. In mice with the APOE4 gene, reducing Nell2 levels reverses neuronal changes and improves cognitive function.
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
A team from SickKids discovered a therapeutic target in fat tissue that improves cellular function and reduces inflammation. Low-dose homoharringtonine treatment selectively eliminates senescent cells, improving metabolic problems and preserving lean mass.
The new joint department combines expertise in medical devices, neuroengineering, imaging science, and more to advance biomedical research and translate discoveries into meaningful health advances. The partnership aims to accelerate the translation of discoveries into improvements in human health.
Researchers from Kobe University have designed a small mirror protein that disables amyloid-beta, a causal factor of Alzheimer's disease. The approach uses the principle of 'chirality' to bind to the protein, inhibiting its aggregation and potential for brain cell damage.
A new model of brain wiring could shorten the path to developing medicines for multiple sclerosis and other degenerative brain diseases. The model, made of a water-filled gel, replicates the physical properties of human axons and has been successfully grown from human cells in the laboratory.
The International Society for Stem Cell Research has named Stem Cell Reports as the official conference journal for the Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening meeting. The journal will focus on high-impact research spanning basic discovery to clinical translation in stem cell science.
The latest volume of SLAS Discovery highlights advances in 3D cell culture and novel technologies for drug discovery. Small molecule cytokine antagonists and a versatile ELISA for PPI inhibitor screening are among the key findings.
This issue highlights advancements in drug discovery, synthetic biology, and laboratory digitalization. SLAS Technology emphasizes scientific and technical advances that enable improved biomedical research and development.
The latest SLAS Technology volume showcases how AI, automation, and portable technologies are transforming drug discovery and diagnostics. This advancement enables the development of innovative therapeutic solutions and improved patient care.
A team of researchers at MSU used machine learning to predict how chemicals will influence gene expression, leading to the discovery of promising compounds for the treatment of liver cancer and a chronic lung disease. The study results from years of interdisciplinary work across multiple disciplines and institutes.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Jeonbuk National University researchers have developed DDINet, a lightweight and scalable model that can accurately predict drug-drug interactions for new, unseen drugs. This approach avoids overfitting to training data and is designed to handle binary and multi-classification tasks.
Researchers developed a machine-learning system that predicts how molecules form, cutting lab work time from months to days and reducing costs. The system uses asymmetric cross-coupling reactions to build complex compounds and can be applied across fields, deepening our understanding of chemistry.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers at Goethe University are developing non-hormonal contraceptives to address declining pill use and side effects. The PREVENT project aims to create safe and effective alternatives, focusing on small molecules that block proteins in sperm or egg cells.
Researchers from MedUni Vienna have developed a new approach to drug discovery by targeting intracellular signalling proteins, such as β-arrestins, to control disease-relevant signalling pathways. This approach holds promise for personalized therapies, particularly for the treatment of neurological diseases.
Researchers have developed a bacterial system to create millions of potential drug molecules that can target difficult-to-treat cancers. The approach combines chemical peptide stabilisation with the TBS assay to screen for effective peptides, which can then be tested in more complex tissue models and animal studies.
A new study finds that a novel GLP-1 receptor agonist, Exendin-4-Phe (Ex-Phe-1), preserves glycemic control while reducing malaise and vomiting behaviors in preclinical models. The compound uses biased agonism to selectively activate certain signaling pathways, achieving desired effects without triggering others.
Researchers at Osaka Metropolitan University found that targeting the glutamine transporter ASCT2 can suppress cell growth and induce apoptosis in synovial sarcoma cells. This study suggests a new approach for treating this aggressive malignant tumor by cutting off its nutrient supply.